Catalyst Pharmaceuticals, Inc. (CPRX) Institutional Ownership

Ownership Summary

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) appears in 365 institutional 13F filings for the quarter ending December 2025.

• These investors held 81.8% of outstanding shares in December 2025, down from 83.5% in September 2025.
• Their total shares held in CPRX increased 2.58% from the prior quarter, while the number of investors in Catalyst Pharmaceuticals increased 9.28% year over year.
• Of these 365 funds, 184 grew their exposure to Catalyst Pharmaceuticals, 128 cut back, and 53 maintained positions.
• Institutional investors collectively held 103.9Mn shares in Catalyst Pharmaceuticals as of December 2025, up by 2.62Mn shares quarter on quarter, and up 2.79Mn shares year over year.
• BlackRock, Inc. leads ownership in CPRX with 18.77Mn shares as of December 31, 2025, equal to 14.77% of outstanding shares.
• Top purchasers of CPRX stock for the quarter ending December 2025 included VANGUARD CAPITAL MANAGEMENT LLC (5.12Mn), VANGUARD PORTFOLIO MANAGEMENT LLC (2.48Mn), Janus Henderson Group Plc (2.28Mn), AMERICAN CENTURY COMPANIES INC (1.11Mn), Bank Of America Corp /De/ (836.7K).
• Leading sellers of Catalyst Pharmaceuticals shares for the quarter ending December 2025 were Fundsmith LLP (2.52Mn), Goldman Sachs Group Inc (974.35K), DEERFIELD MANAGEMENT COMPANY, L.P. (967.56K), ARROWSTREET CAPITAL, LIMITED PARTNERSHIP (661.89K), Swedbank AB (616.13K).
• Catalyst Pharmaceuticals's 10 largest shareholders as of December 2025 include BlackRock, Inc. (18.77Mn), State Street Corp (6.86Mn), VANGUARD CAPITAL MANAGEMENT LLC (5.12Mn), AMERICAN CENTURY COMPANIES INC (4.14Mn), Janus Henderson Group Plc (4.0Mn), DEERFIELD MANAGEMENT COMPANY, L.P. (3.94Mn), DIMENSIONAL FUND ADVISORS LP (3.43Mn), Bank Of America Corp /De/ (3.04Mn), GEODE CAPITAL MANAGEMENT, LLC (2.97Mn), Morgan Stanley (2.69Mn) per Business Quant data.